Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propensity-matched study

医学 肝细胞癌 队列 内科学 乙型肝炎病毒 胃肠病学 HBeAg 免疫学 肿瘤科 病毒 乙型肝炎表面抗原
作者
Qing-Jing Chen,Kongying Lin,Zhi-Wen Lin,Bing Zhang,Mingqiang Liu,Jianxi Zhang,Qi-Zhen Huang,Kecan Lin,Jinyu Zhang,Fuqun Wei,Peng-Hui You,You Song,Jiang Ya-bin,Hui Zhang,Zhiqing Cheng,Cong-Ren Wang,Yongyi Zeng
出处
期刊:International Immunopharmacology [Elsevier BV]
卷期号:125: 111098-111098 被引量:3
标识
DOI:10.1016/j.intimp.2023.111098
摘要

The efficacy and safety of tyrosine kinase inhibitors (TKIs) combined with anti-PD-1 antibodies (α-PD-1) in advanced hepatocellular carcinoma (HCC) with high hepatitis B virus (HBV) DNA levels (>500 IU/mL) remain unclear. We retrospectively assessed patients from seven medical institutions diagnosed with HBV-related HCC, undergoing treatment with TKIs and α-PD-1 in conjunction with antiviral therapies. Based on HBV-DNA levels, patients were categorized into either high (HHBV-DNA, >500 IU/mL) or low HBV-DNA (LHBV-DNA, ≤500 IU/mL) cohorts Propensity score matching (PSM) was used to minimize baseline imbalance between groups. 149 patients were included, with 66 patients exhibiting HBV-DNA > 500 IU/mL and 83 patients presenting HBV-DNA ≤ 500 IU/mL. Compared with the LHBV-DNA cohort, the HHBV-DNA cohort had a greater incidence of serum HBeAg positivity, tumor diameter ≥ 10 cm, and vascular invasion. Following PSM, 57 individuals were enrolled in each group. Oncological outcomes were comparable between HHBV-DNA and LHBV-DNA cohorts before and after PSM. Before PSM, the median PFS and OS were 6.1 months and 17.5 months in the HHBV-DNA cohort and 6.7 months and 19.3 months in the LHBV-DNA cohort (all P > 0.05). After PSM, the median PFS and OS were 6.0 months and 19.5 months in the HHBV-DNA cohort and 6.0 months and 17.1 months in the LHBV-DNA cohort, respectively (all P > 0.05). Safety profiles were equivalent across cohorts with no fatal incidents reported. Seven patients (4.7 %) had HBV reactivation. 1 (0.7 %) from HHBV-DNA and 6 (4.0 %) from LHBV-DNA (P = 0.134). Only one patient developed HBV-related hepatitis. The effectiveness and safety of TKIs plus α-PD-1 in advanced HCC with HBV-DNA > 500 IU/mL were not compromised in the context of concomitant antiviral therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
柳行天完成签到 ,获得积分10
3秒前
科目三应助阳光易真采纳,获得30
8秒前
yoyo发布了新的文献求助10
8秒前
思源应助Wl采纳,获得10
10秒前
共享精神应助橘笙采纳,获得10
11秒前
耍酷问兰发布了新的文献求助10
12秒前
科研通AI2S应助nczpf2010采纳,获得10
14秒前
搜集达人应助杜兰特工队采纳,获得10
19秒前
热心市民小红花应助牛马采纳,获得10
21秒前
热心市民小红花应助牛马采纳,获得10
21秒前
21秒前
Ava应助WJM采纳,获得10
25秒前
科研通AI2S应助nczpf2010采纳,获得10
26秒前
酷酷飞烟发布了新的文献求助10
26秒前
Bressanone发布了新的文献求助10
28秒前
李健的小迷弟应助老吴采纳,获得10
28秒前
大气的雅山完成签到,获得积分10
30秒前
shaoshao86完成签到,获得积分10
36秒前
36秒前
华仔应助科研通管家采纳,获得10
36秒前
逆时针应助科研通管家采纳,获得10
36秒前
MchemG应助科研通管家采纳,获得10
36秒前
研友_VZG7GZ应助科研通管家采纳,获得10
36秒前
wang应助科研通管家采纳,获得10
36秒前
wang应助科研通管家采纳,获得10
36秒前
ding应助科研通管家采纳,获得10
36秒前
上官若男应助科研通管家采纳,获得10
37秒前
思源应助科研通管家采纳,获得10
37秒前
田様应助科研通管家采纳,获得10
37秒前
小北发布了新的文献求助10
37秒前
NexusExplorer应助Quinna采纳,获得10
39秒前
40秒前
40秒前
量子星尘发布了新的文献求助10
42秒前
WJM发布了新的文献求助10
46秒前
老吴发布了新的文献求助10
47秒前
48秒前
佳语妍说完成签到,获得积分10
49秒前
50秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989069
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253589
捐赠科研通 3269939
什么是DOI,文献DOI怎么找? 1804851
邀请新用户注册赠送积分活动 882074
科研通“疑难数据库(出版商)”最低求助积分说明 809073